Bulk Pharmaceutical API Sources for VONJO

Bulk Pharmaceutical API Sources for VONJO

Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical		2023-05-7C06610

Bulk Active Pharmaceutical Ingredient (API) Sources for Vonjo (Pacritinib)

Last updated: February 19, 2026

Vonjo (pacritinib) is a kinase inhibitor indicated for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis (MF) who have a platelet count below 50 x 10^9/L. Sourcing bulk Active Pharmaceutical Ingredient (API) for Vonjo is critical for pharmaceutical manufacturers to ensure a consistent and compliant supply chain. This analysis identifies potential API manufacturers and key considerations for sourcing pacritinib.

What is the chemical structure and regulatory status of pacritinib?

Pacritinib is chemically known as 3-(4-((4-(1-methylpiperidin-4-yl)butyl)amino)thieno[3,2-d]pyrimidin-2-yl)benzonitrile. Its molecular formula is C25H31N5S. The drug is approved by the U.S. Food and Drug Administration (FDA) and is also approved in Europe. The regulatory approval status confirms that pacritinib has undergone rigorous review and meets established quality and safety standards.

Who are the key manufacturers and suppliers of pacritinib API?

The development and manufacturing of pacritinib API are complex, involving specialized chemical synthesis and strict quality control. Major pharmaceutical companies or their contracted contract manufacturing organizations (CMOs) are typically involved in API production.

The originator company for Vonjo is CTI BioPharma Corp. (now part of Sobi). CTI BioPharma would have established the initial manufacturing process and qualified API suppliers. While CTI BioPharma itself may not be the direct manufacturer of the bulk API, it would oversee the supply chain.

Identifying specific, publicly disclosed bulk API suppliers for pacritinib is challenging as these relationships are often proprietary. However, the following types of entities are involved in or capable of API manufacturing for complex molecules like pacritinib:

• Contract Development and Manufacturing Organizations (CDMOs): These organizations specialize in the development and manufacturing of APIs and finished drug products for pharmaceutical companies. Companies with expertise in complex heterocyclic chemistry, chiral synthesis, and GMP (Good Manufacturing Practice) compliance are prime candidates. Examples of global CDMOs include:

  • Lonza
  • Catalent
  • Thermo Fisher Scientific (Patheon)
  • Evonik Industries
  • WuXi AppTec
  • Porton Pharma Solutions

• Specialized API Manufacturers: Certain companies focus exclusively on the production of APIs, often for a range of therapeutic areas. These may include companies based in regions with established pharmaceutical manufacturing sectors such as India and China.

  • Indian API Manufacturers: India is a significant global hub for API production, known for its cost-effectiveness and large-scale manufacturing capabilities. Companies like Dr. Reddy's Laboratories, Cipla, Sun Pharmaceutical Industries, and Aurobindo Pharma have broad API portfolios and often possess the capabilities for complex synthesis.
  • Chinese API Manufacturers: China also plays a crucial role in global API supply. Companies such as Hengrui Medicine, Shanghai Pharmaceuticals Holding, and Zhejiang Huahai Pharmaceutical are prominent players with advanced manufacturing facilities.

• In-house Manufacturing by Originator/Acquirer: While less common for complex, patented drugs during their initial lifecycle, the originating or acquiring pharmaceutical company might maintain some in-house API manufacturing capabilities for strategic control over supply or for specific intermediates. In the case of Vonjo, Sobi, after acquiring CTI BioPharma, would now oversee the API supply chain.

Table 1: Potential Categories of Pacritinib API Manufacturers

Manufacturer Category	Key Capabilities	Typical Geographic Presence
Contract Development and Manufacturing Organizations (CDMOs)	Process development, scale-up, cGMP manufacturing, analytical services, regulatory support, supply chain management.	Global (North America, Europe, Asia)
Specialized API Manufacturers	High-volume API synthesis, specific chemical expertise (e.g., heterocyclic chemistry, chiral synthesis), cost-efficient production.	India, China, Europe, North America
Integrated Pharmaceutical Companies	Full-spectrum drug development and manufacturing, from API to finished dosage form. May involve dedicated internal API production units or strategic partnerships.	Global

What are the key chemical synthesis steps and challenges in pacritinib API production?

The synthesis of pacritinib involves multi-step organic chemistry. A simplified overview of potential key steps and associated challenges includes:

1. Formation of the Thieno[3,2-d]pyrimidine Core: This heterocyclic core is central to pacritinib's structure. Its synthesis likely involves cyclization reactions starting from thiophene derivatives and pyrimidine precursors. Challenges include achieving regioselectivity and high yields in cyclization steps.
2. Introduction of the Benzonitrile Moiety: Attaching the 3-cyanophenyl group to the thienopyrimidine core requires specific coupling reactions, such as palladium-catalyzed cross-coupling (e.g., Suzuki or Sonogashira coupling), which are sensitive to reaction conditions and require careful control of catalyst loading and ligand choice.
3. Attachment of the Alkylamino Side Chain: The butylamino linkage to the piperidine ring needs to be formed efficiently. This might involve reductive amination or nucleophilic substitution reactions. The synthesis of the 4-(1-methylpiperidin-4-yl)butylamine intermediate itself is a multi-step process requiring control over stereochemistry if applicable and efficient protection/deprotection strategies.
4. Chiral Control (if applicable): While pacritinib is not a chiral molecule as presented, intermediates or the final molecule could potentially have chiral centers depending on the specific synthetic route employed by a manufacturer. If stereoisomers were involved, chiral synthesis or resolution techniques would be critical.
5. Impurity Profiling and Control: Complex multi-step syntheses invariably generate process-related impurities, including starting material residues, by-products, and degradation products. Rigorous analytical method development and validation are essential to identify, quantify, and control these impurities to meet stringent regulatory limits (ICH guidelines).
6. Polymorphism: APIs can exist in different crystalline forms (polymorphs), which can affect their solubility, dissolution rate, stability, and bioavailability. Identifying and controlling the desired polymorphic form during crystallization is a critical aspect of API manufacturing.
7. Scale-up and Process Optimization: Transitioning a synthesis from laboratory scale to commercial manufacturing presents significant challenges. Process parameters (temperature, pressure, reaction time, reagent addition rates) must be optimized for safety, efficiency, and reproducibility at large scales.
8. Solvent Selection and Waste Management: The choice of solvents impacts reaction efficiency, safety, and environmental footprint. Minimizing the use of hazardous solvents and managing waste streams in an environmentally responsible manner are crucial considerations.

What are the critical quality attributes (CQAs) and regulatory requirements for pacritinib API?

Manufacturers of pacritinib API must adhere to strict quality standards and regulatory guidelines to ensure the safety and efficacy of the final drug product. Key CQAs and regulatory requirements include:

• Identity: Confirmation that the API is indeed pacritinib. This is typically verified using spectroscopic methods like Nuclear Magnetic Resonance (NMR), Infrared (IR) spectroscopy, and Mass Spectrometry (MS).
• Purity: The absence or acceptable levels of impurities. This includes:
  • Organic Impurities: Related substances arising from the synthesis, such as starting materials, intermediates, by-products, and degradation products. Limits are defined by ICH Q3A(R2).
  • Inorganic Impurities: Residues from catalysts or reagents, often metallic impurities, which are controlled according to ICH Q3D.
  • Residual Solvents: Solvents used in the manufacturing process. Limits are specified by ICH Q3C.
• Assay (Potency): The quantitative measure of the amount of pacritinib present, usually expressed as a percentage. Typically determined by High-Performance Liquid Chromatography (HPLC) with UV detection.
• Water Content: Controlled using Karl Fischer titration, as excess moisture can affect stability.
• Heavy Metals: Limits are set to ensure patient safety.
• Particle Size Distribution (PSD): Important for downstream processing (formulation) and can influence dissolution rates and bioavailability.
• Polymorphic Form: Consistent production of the desired crystalline form.
• Microbial Limits: For APIs that are not terminally sterilized, microbial contamination must be controlled.

Regulatory Requirements:

• Good Manufacturing Practices (GMP): API manufacturers must comply with cGMP regulations established by regulatory bodies such as the FDA (21 CFR Parts 210 and 211), EMA, and other national health authorities. This encompasses all aspects of production, quality control, and quality assurance.
• Drug Master Files (DMFs): API manufacturers typically submit a DMF to regulatory agencies (e.g., FDA's Type II DMF). This confidential document details the chemistry, manufacturing, and controls (CMC) of the API, including its synthesis, specifications, stability data, and packaging. Pharmaceutical companies referencing the DMF in their drug product applications can gain access to relevant sections.
• ICH Guidelines: Compliance with International Council for Harmonisation (ICH) guidelines is essential, particularly:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
  • ICH Q3A(R2): Impurities in New Drug Substances
  • ICH Q3C(R8): Impurities: Guideline for Residual Solvents
  • ICH Q3D(R2): Guideline for Elemental Impurities
  • ICH Q1A(R2): Stability Testing of New Drug Substances and Products

What are the supply chain considerations and risk mitigation strategies for pacritinib API?

Securing a reliable and high-quality supply of pacritinib API involves proactive supply chain management and risk mitigation.

Key Supply Chain Considerations:

• Supplier Qualification: Thoroughly vetting potential API manufacturers is paramount. This involves:
  • Quality Audits: On-site inspections to assess GMP compliance, quality systems, manufacturing capabilities, and analytical testing procedures.
  • Financial Stability: Ensuring the supplier is financially sound to maintain long-term production.
  • Regulatory History: Reviewing past regulatory inspections and any compliance issues.
  • Technical Expertise: Verifying their experience with similar chemical syntheses and complex molecules.
• Dual Sourcing Strategy: Establishing relationships with at least two qualified API suppliers can mitigate risks associated with single-source dependency. This provides a backup in case of supply disruptions, quality issues, or geopolitical instability affecting one supplier.
• Geographic Diversification: Sourcing from suppliers in different geographical regions can reduce vulnerability to regional issues such as natural disasters, trade disputes, or political unrest.
• Intellectual Property (IP) Protection: Ensuring that any technology transfer or supply agreement respects existing patents and does not infringe on intellectual property rights. For pacritinib, patent protection would be a significant factor.
• Lead Times and Inventory Management: Understanding the manufacturing lead times for pacritinib API and implementing appropriate inventory management strategies to avoid stock-outs while minimizing holding costs.
• Logistics and Transportation: Establishing reliable logistics for the secure and compliant transportation of the API from the manufacturing site to the drug product manufacturing facility, adhering to temperature and handling requirements.
• Regulatory Compliance of Suppliers: Verifying that all chosen suppliers meet the cGMP standards of the target markets for Vonjo.
• Contractual Agreements: Comprehensive contracts with suppliers that clearly define quality standards, delivery schedules, pricing, responsibilities, and termination clauses.

Risk Mitigation Strategies:

• Robust Quality Agreements: Implementing detailed quality agreements with API suppliers that outline specific quality control measures, change control procedures, and notification requirements for deviations.
• Early Engagement with Suppliers: Involving API manufacturers early in the drug development process allows for collaborative process development and ensures that the API is produced to meet the required specifications from the outset.
• Contingency Planning: Developing contingency plans for various disruption scenarios, such as natural disasters, supplier plant failures, or transportation issues. This might include identifying alternative manufacturing sites or exploring different synthetic routes.
• Supply Chain Visibility: Utilizing technology to enhance visibility into the supply chain, tracking raw material movements and API production status.
• Scenario Planning and Stress Testing: Periodically conducting scenario planning exercises to evaluate the resilience of the supply chain to potential disruptions and stress-testing the mitigation strategies.
• Regular Audits and Performance Monitoring: Continuous monitoring of supplier performance through regular audits and key performance indicators (KPIs) to identify and address potential issues proactively.

What is the patent landscape for pacritinib and its impact on API sourcing?

The patent landscape for pacritinib is a critical factor influencing API sourcing. Patents can protect the compound itself, its methods of use, and potentially manufacturing processes.

• Composition of Matter Patents: These are the strongest patents, protecting the molecule of pacritinib itself. These patents typically have a long lifespan (often 20 years from the filing date, plus potential patent term extensions). While Vonjo is approved, it is likely still under patent protection, limiting generic competition and ensuring CTI BioPharma (now Sobi) has market exclusivity.
• Method of Use Patents: These patents cover specific indications or patient populations for which pacritinib can be used.
• Process Patents: These patents may protect specific synthetic routes or key intermediate steps used in the manufacturing of pacritinib API.

Impact on API Sourcing:

• Exclusivity: During the period of patent protection, only the patent holder or their licensees can legally manufacture and sell pacritinib API for the patented indications. This means that any company seeking to supply pacritinib API for the Vonjo brand must be approved by Sobi, likely through a contract manufacturing agreement.
• Generic API Manufacturing: Once the key patents expire, generic manufacturers can enter the market. This opens up opportunities for a wider range of API suppliers, potentially leading to increased competition and price reductions. Generic API manufacturers would need to develop their own non-infringing synthetic routes or wait for patent expiry.
• Freedom to Operate (FTO) Analysis: Any company looking to manufacture pacritinib API, whether for the originator or for generic markets, must conduct a thorough FTO analysis to ensure their chosen manufacturing process does not infringe on existing patents.

As of recent information, pacritinib's core patents are held by CTI BioPharma. Sobi acquired CTI BioPharma, thus controlling the patent estate. Companies looking to manufacture pacritinib API would need to either contract with Sobi's designated manufacturers or await patent expiry to produce for the generic market, while ensuring non-infringement of any remaining valid process patents.

Key Takeaways

• Pacritinib API manufacturing requires specialized expertise in complex organic synthesis and stringent adherence to cGMP standards.
• Potential API suppliers include global CDMOs and specialized API manufacturers, particularly those in India and China.
• Key quality attributes for pacritinib API include identity, purity (organic, inorganic, residual solvents), assay, water content, and polymorphic form.
• Supply chain resilience can be achieved through dual sourcing, geographic diversification, robust supplier qualification, and comprehensive contractual agreements.
• The patent landscape dictates exclusivity periods, influencing whether API sourcing is conducted under contract with the originator or for the generic market post-patent expiry.

Frequently Asked Questions

What is the typical batch size for pacritinib API production?

Typical batch sizes for complex APIs like pacritinib can range from tens of kilograms to hundreds of kilograms, depending on the supplier's manufacturing capacity and the anticipated market demand for Vonjo.

How long does it take to qualify a new API supplier for pacritinib?

Qualifying a new API supplier typically takes 6 to 18 months, involving thorough audits, quality assessments, sample testing, and potentially small-scale validation batches.

Are there specific impurities that are particularly challenging to control in pacritinib synthesis?

Complex heterocyclic syntheses often present challenges in controlling regioisomers and by-products from incomplete reactions or side reactions. Impurities related to the alkylamino side chain and its attachment are also potential areas of concern.

What is the shelf-life of pacritinib API under recommended storage conditions?

The shelf-life of pacritinib API is determined by stability studies conducted according to ICH guidelines. A typical shelf-life for a stable API is often 2 to 5 years when stored under controlled conditions (e.g., protected from light, moisture, and at specified temperatures).

Can pacritinib API be sourced from multiple suppliers simultaneously for the branded product?

Yes, pharmaceutical companies often engage in dual or multi-sourcing strategies for critical APIs like pacritinib to ensure supply continuity and mitigate risks, provided all suppliers meet the stringent qualification and quality requirements and have been approved by the regulatory authorities.

Citations

[1] CTI BioPharma Corp. (n.d.). Pacritinib. Retrieved from https://www.ctibiopharma.com/pipeline/pacritinib/ (Note: This link may change or be redirected after Sobi's acquisition.)

[2] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files-dmfs

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guidelines. Retrieved from https://www.ich.org/products/guidelines